Tag
Fredun Pharmaceuticals Limited
5 articles
Fredun Pharmaceuticals concluded a strong fiscal year 2026, reporting a 67% year-over-year increase in net profit to ₹3,320.69 lakhs, alongside a 40% revenue jump to ₹63,332.65 lakhs. The company's annual general meeting approved a 7% dividend and a 2:1 bonus issue, reflecting robust financial performance and shareholder returns. Strategic expansion initiatives, including the establishment of new subsidiaries Fredun Retail and One Pet Stop, were supported by preferential share issuances and increased borrowing limits, positioning the company for continued growth despite auditor observations regarding unclaimed dividends.
Fredun Pharmaceuticals AGM Approves 7% Dividend and Bonus Issue
Fredun Pharmaceuticals held its 39th AGM on June 30, 2026, via video conference to vote on eleven resolutions.
Shareholders approved a 7% dividend for FY26 and a bonus issue of equity shares, both wit
Fredun Pharmaceuticals AGM Approves Bonus Shares
Fredun Pharmaceuticals held its 39th AGM on June 30, 2026, approving 11 resolutions including financial statements and director appointments.
Key resolutions passed include a bonus share issue, increa
Fredun Pharmaceuticals Q4 FY26 Net Profit Up 56.5%
Fredun Pharmaceuticals reported Q4 FY26 net profit of ₹11.07 crore, a 56.47% YoY growth, with total income up 27.27% to ₹213 crore.
The company announced new product launches in hormonal and anti-agin
Fredun Pharmaceuticals Q4 FY26 Earnings Call Recording
Fredun Pharmaceuticals disclosed audio recording of Q4 FY26 earnings conference call held on 10th June 2026.
Recording covers audited financial results for quarter and year ended 31st March 2026.
Audi
Fredun Pharmaceuticals AGM Approves 67% Profit Growth, Dividend
Fredun Pharmaceuticals reported 67% YoY net profit growth to ₹3,320.69 lakhs with 40% revenue increase to ₹63,332.65 lakhs for FY26.
The company convened its 39th AGM to approve a 7% dividend and 2:1